CervoMed Inc.

CervoMed Inc.

CRVO·NASDAQ

$5.50

-0.36%
HealthcareBiotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$50.89M
EPS-2.0200
P/E Ratio-1.16
Earnings Date03/16/2026

crvo

Cash at Beginning of Period

Last Annual Value

7.79M

3-Year CAGR

-25%

5-Year CAGR

-1%

10-Year CAGR

41%

CervoMed Inc.

CervoMed Inc. Competitors Analysis of Cash at Beginning of Period

CRVO · NASDAQ
CompanyCash at Beginning of Period
CAGR 3Y
CAGR 5Y
CAGR 10Y
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
7.79M
23.9%-15.9%14.6% 
1.44M
-58.4%-4.9%N/A
58.81M
-31.2%-24.2%-5.0%
38.98K
-39.0%-49.9%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
59.40M
-38.7%-7.7%-2.4%
CLNN logo
Clene Inc.
NASDAQ:CLNN
12.21M
-12.8%-27.1%N/A
112.22M
-4.9%3.9%N/A
3.54M
-51.0%5.7%32.5%
17.68M
9.6%114.3%N/A
40.88M
-27.9%-35.3%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
25.23M
-18.2%-27.6%-6.6%
CervoMed Inc.

CervoMed Inc. Fair Value Envelope

CRVO · NASDAQ

Our analysis suggests that CRVO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.5, this represents a potential HIDDEN relative to our calculated worth for CervoMed Inc..

Intrinsic Value
Current Price: $5.5